HomeInsightsResults

Vista Pharmaceuticals Ltd Quarterly Result

Vista Pharmaceuticals Ltd Quarterly Result

stocks purchased

₹ 0.0 Cr

Volume Transacted

(Nov 22, 2024)

stocks purchased

6.1 K

Stocks Traded

(Nov 22, 2024)

Last Updated on: Nov 24, 2024

Image

Vista Pharmaceuticals Ltd

NSE: VISTAPHARMA

Net Profit

₹ -0.97

Last updated on: Nov 24, 2024

Key Highlights

  • The revenue of Vista Pharmaceuticals Ltd for the Sep '24 is ₹ 2.5 crore as compare to the Jun '24 revenue of ₹ 1.87 crore. This represent the growth of 33.68984%.
  • The ebitda of Vista Pharmaceuticals Ltd for the Sep '24 is ₹ -0.82 crore as compare to the Jun '24 ebitda of ₹ -0.71 crore. This represent the growth of 15.492961%.
  • The net profit of Vista Pharmaceuticals Ltd for the Sep '24 is ₹ -0.97 crore as compare to the Jun '24 net profit of ₹ -0.86 crore. This represent the growth of 12.7907%.

Results Analysis

Market Price of Vista Pharmaceuticals Ltd

1M

1Y

3Y

5Y

Monitoring Vista Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
22 Nov 202411.67
21 Nov 202411.34
19 Nov 202411.88
18 Nov 202412.1
14 Nov 202412.25
13 Nov 202412.03
12 Nov 202412.6
11 Nov 202412.35
08 Nov 202412.53
07 Nov 202412.85

Historical Revenue of Vista Pharmaceuticals Ltd

No data available

* All values are in crore

Historical EBITDA of Vista Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Net Profit of Vista Pharmaceuticals Ltd

No data available

* All values are in crore

Vista Pharmaceuticals Ltd News Hub

News

Vista Pharmaceuticals to convene board meeting

Vista Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 N...

Read more

08 Nov 202415:20

News

Vista Pharmaceuticals to conduct AGM

Vista Pharmaceuticals announced that the 33th Annual General Meeting (AGM) of the company ...

Read more

10 Sep 202410:41

News

Vista Pharmaceuticals to discuss results

Vista Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 A...

Read more

06 Aug 202414:28

News

Vista Pharmaceuticals announces board meeting date

Vista Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 M...

Read more

24 May 202416:36

News

Vista Pharmaceuticals to hold EGM

Vista Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Compan...

Read more

14 Feb 202416:53

News

Vista Pharmaceuticals to hold board meeting

Vista Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 10 F...

Read more

03 Feb 202416:44

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQ's For Vista Pharmaceuticals Ltd Quarterly Result

What is the EPS of Vista Pharmaceuticals Ltd stock?

The Earnings Per Share (EPS) of Vista Pharmaceuticals Ltd is 0.0. An EPS is the amount of net income attributed to each share of a common stock.

How is Vista Pharmaceuticals Ltd EPS calculated?

The EPS of Vista Pharmaceuticals Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Vista Pharmaceuticals Ltd report its EPS?

Vista Pharmaceuticals Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Vista Pharmaceuticals Ltd EPS?

Factors that influence the EPS of Vista Pharmaceuticals Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Vista Pharmaceuticals Ltd EPS growth indicate future performance?

Yes, consistent growth in Vista Pharmaceuticals Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*